Sight Diagnostics, an Israel-based medical diagnostics device developer backed by conglomerate Access Industries, has secured $28m from unnamed investors, Globes has reported, citing news from Access subsidiary Clal Biotechnology Industries.
Although the investors were not disclosed, announcement stated that Anatomy, a fund 50% held by Clal Biotechnology, will own a 7% stake in Sight once the round has closed.
Founded in 2011, Sight Diagnostics has created a machine learning-equipped system that allows doctors to test a patient’s blood in the clinic.
The company’s lead product, the Parasight System, is being used to test for malaria in developing countries, and it is in the process of developing a blood count test that utilises its technology.
The latest funding comes after $25m round in series A and B funding from investors including venture capital firm Innovation Endeavors that was announced in July 2018.
Sight Diagnostics has also raised a total of approximately $9.9m from three rounds on equity crowdfunding platform OurCrowd, which identified pharmaceutical company Haisco, Go Capital and Innovation Endeavors as co-investors.